Hereditary and acquired antithrombin deficiency: Epidemiology, pathogenesis and treatment options

Drugs

Volumn 67, Issue 10, 2007, Pages 1429-1440

  Maclean, Peter S ^a   Tait, R Campbell ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTITHROMBIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; RECOMBINANT ANTITHROMBIN III; THROMBATE III; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; BIRTH; BLEEDING; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARDIOPULMONARY BYPASS; DISEASE SEVERITY; GENETIC DISORDER; HIGH RISK POPULATION; HUMAN; IMMOBILIZATION; INTENSIVE CARE UNIT; LYMPHATIC LEUKEMIA; PATHOGENESIS; POSTPARTUM HEMORRHAGE; PREGNANCY; PREVALENCE; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEPSIS; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; BLOOD COMPONENT TRANSFUSION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREVALENCE; RECOMBINANT PROTEINS; SEPSIS;

EID: 34347393477     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767100-00005     Document Type: Review

References (72)

1. Hunt LT, Dayhoff MO. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun 1980 Jul 31; 95 (2): 864-71
2. Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002 Apr 1; 99 (7): 2455-8
3. Lane DA, Kunz G, Olds RJ, et al. Molecular genetics of anantithrombin tithrombin deficiency. Blood Rev 1996 Jun; 10 (2): 59-74
4. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002 Nov; 126 (11): 1326-36
5. Walker CPR, Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth 2002 Jun; 88 (6): 848-63
6. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24 (1): 19-25
7. Wiedermann CJ, Romisch J. The anti-inflammatory actions of antithrombin: a review. Acta Med Austriaca 2002; 29 (3): 89-92
8. White B, Perry D. Acquired antithrombin deficiency in sepsis. Br J Haematol 2001 Jan; 112 (1): 26-31
9. Egeberg O. Inherited fibrinogen abnormality causing thrombophilia. Thromb Diath Haemorrh 1967 Feb 28; 17 (1-2): 176-87
10. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997 Jan; 77 (1): 197-211
11. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency: incidence and clinical features. Am J Med 1989 Sep 11; 87 (3B): 34-8S
12. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975 Jan 16; 292 (3): 146-51
13. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994 May; 87 (1): 106-12
14. Harper PL, Luddington RJ, Daly M, et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991 Mar; 77 (3): 360-4
15. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997 Mar; 77 (3): 444-51
16. McColl M, Tait RC, Walker ID, et al. Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 1996 Oct; 7 (7): 689-94
17. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998 Oct 1; 92 (7): 2353-8
18. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987 Dec 18; 58 (4): 1094
19. Bushman JE, Palmieri D, Whinna HC, et al. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000 Jul; 24 (7): 559-65
20. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998 Jun; 79 (6): 1166-70
21. Wickstrom K, Edelstam G, Lowbeer CH, et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64 (1): 31-40
22. Morikawa M, Yamada T, Kataoka S, et al. Changes in antithrombin activity and platelet counts in the late stage of twin and triplet pregnancies. Semin Thromb Hemost 2005 Jun; 31 (3): 290-6
23. Tait RC, Walker ID, Islam SI, et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993 Jul; 84 (3): 476-80
24. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002 Oct 1; 100 (7): 2403-5
25. Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006; 43 (3): 249-90
26. van Boven HH, Vandenbroucke JP, Westendorp RG, et al. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997 Mar; 77 (3): 452-5
27. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999 Dec 1; 94 (11): 3702-6
28. Demers C, Ginsberg JS, Hirsh J, et al. Thrombosis in antithrombin-III- deficient persons: report of a large kindred and literature review. Ann Intern Med 1992 May 1; 116 (9): 754-61
29. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006 Jan; 132 (2): 171-96
30. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997 Oct; 78 (4): 1183-8
31. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996 Oct 5; 348 (9032): 913-6
32. Krabbendam I, Franx A, Bots ML, et al. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2005 Feb 1; 118 (2): 143-53
33. Martinez MA, Pena JM, Fernandez A, et al. Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. Crit Care Med 1999 Jul; 27 (7): 1303-8
34. Kessler CM, Tang Z, Jacobs HM, et al. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997 Jun 15; 89 (12): 4393-401
35. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000 Feb 15; 95 (4): 1117-23
36. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003 Jan 25; 109 (2-3): 73-81
37. Paternoster D, Stella A, Simioni P, et al. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet 1994 Dec; 47 (3): 215-21
38. Sayin M, Varol FG, Sayin NC. Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy. Eur J Obstet Gynecol Reprod Biol 2005 Dec 1; 123 (2): 183-7
39. Levy JH, Despotis GJ, Szlam F, et al. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002 May; 96 (5): 1095-102
40. Ranucci M, Ditta A, Boncilli A, et al. Determinants of antithrombin consumption in cardiac operations requiring cardicy. opulmonary bypass. Perfusion 2004 Jan; 19 (1): 47-52
41. Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996 Jan; 82 (1): 13-21
42. Ranucci M, Frigiola A, Menicanti L, et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005 Feb; 33 (2): 355-60
43. Haemostasis and Thrombosis Task Force BCfSiH. Investigation and management of heritable thrombophilia. Br J Haematol 2001 Sep; 114 (3): 512-28
44. Menache D, O'Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990 Jan 1; 75 (1): 33-9
45. Lechner K, Kyrle PA. Antithrombin III concentrates: are they clinically useful? Thromb Haemost 1995 Mar; 73 (3): 340-8
46. Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003 Mar; 43 (3): 390-4
47. Bauer KA. Management of thrombophilia. J Thromb Haemost 2003 Jul; 1 (7): 1429-34
48. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005 Sep; 25 (9): 1992-7
49. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 627-44S
50. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005 Jul 15; 106 (2): 401-7
51. McColl MD, Greer IA. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy. Curr Opin Pulm Med 2004 Sep; 10 (5): 371-5
52. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14 (2): 127-41
53. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998 Jul; 24 (7): 663-72
54. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial [erratum appears in JAMA 2002 Jan 9; 287 (2): 192]. JAMA 2001 Oct 17; 286 (15): 1869-78
55. Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006 Feb; 34 (2): 285-92
56. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006 Jan; 4 (1): 90-7
57. Minneci PC, Deans KJ, Cui X, et al. Antithrombotic therapies for sepsis: a need for more studies. Crit Care Med 2006 Feb; 34 (2): 538-41
58. Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002 Feb; 123 (2): 213-7
59. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000 Sep; 70 (3): 873-7
60. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005 Jul; 130 (1): 107-13
61. Nomura F, Ihara A, Yoshitatsu M, et al. Relationship between coagulation cascade, cytokine, adhesion molecule and aortic aneurysm. Eur J Cardiothorac Surg 2003 Jun; 23 (6): 1034-8
62. Nishiyama T. Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery. Anesth Analg 2006 Apr; 102 (4): 1007-11
63. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003 Aug; 90 (2): 235-44
64. Matsuzaki A, Suminoe A, Hara T. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase. Pediatr Hematol Oncol 2002 Dec; 19 (8): 601-3
65. Morris JD, Harris RE, Hashmi R, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997 Nov; 20 (10): 871-8
66. Schmidt B, Gillie P, Mitchell L, et al. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998 Aug; 158 (2): 470-6
67. Fulia F, Cordaro S, Meo P, et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants? Biol Neonate 2003; 83 (1): 1-5
68. Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998 Jun 15; 91 (12): 4561-71
69. Lu W, Mant T, Levy JH, et al. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg 2000 Mar; 90 (3): 531-4
70. Makris M. Safety of antithrombin III concentrate. Blood 1990 Aug 1; 76 (3): 649-50
71. Chang WS, Harper PL. Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Haemost 1997 Feb; 77 (2): 323-8
72. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996 May 1; 87 (9): 3531-44